ReviewCurrent opinion in lipidology2015
Lysophospholipids in coronary artery and chronic ischemic heart disease.
Review in Current opinion in lipidology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- Myocardial Lipid Metabolism Imbalance: The Pathological Core and Novel Diagnostic-Therapeutic Directions of Cardiovascular Diseases.Journal of biochemical and molecular toxicology · 2026Review
- Synthesis of Autotaxin-Inhibiting Lipid Nanoparticles to Regulate Autophagy and Inflammatory Responses in Activated Macrophages.Tissue engineering and regenerative medicine · 2025Article
- Dilated cardiomyopathy signature metabolic marker screening: Machine learning and multi-omics analysis.Heliyon · 2025Article
- Distinctive serum lipidomic profile of IVIG-resistant Kawasaki disease children before and after treatment.PloS one · 2023Article
- A risk model developed based on necroptosis to assess progression for ischemic cardiomyopathy and identify possible therapeutic drugs.Frontiers in pharmacology · 2022Article
- Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?Metabolites · 2021Article
- Lysophosphatidic Acid May Be a Novel Biomarker for Early Acute Aortic Dissection.Frontiers in surgery · 2021Article
- Ferroptosis as a novel therapeutic target for cardiovascular disease.Theranostics · 2021Review
- Model-based clustering of multi-tissue gene expression data.Bioinformatics (Oxford, England) · 2020Article
- LPATheranostics · 2020Article
- Effects of diet and hyperlipidemia on levels and distribution of circulating lysophosphatidic acid.Journal of lipid research · 2019Article
- Atherosclerosis: integration of its pathogenesis as a self-perpetuating propagating inflammation: a review.Cardiovascular endocrinology & metabolism · 2019Review
- Autotaxin-LPA signaling contributes to obesity-induced insulin resistance in muscle and impairs mitochondrial metabolism.Journal of lipid research · 2018Article
- Lipidomic characterisation discovery for coronary heart disease diagnosis based on high-throughput ultra-performance liquid chromatography and mass spectrometry.RSC advances · 2018Article
- Autotaxin in Pathophysiology and Pulmonary Fibrosis.Frontiers in medicine · 2018Review
- Measurement of Lysophosphatidic Acid and Sphingosine-1-Phosphate by Liquid Chromatography-Coupled Electrospray Ionization Tandem Mass Spectrometry.Methods in molecular biology (Clifton, N.J.) · 2018Article
- FTY720 elevates smooth muscle contraction of aorta and blood pressure in rats via ERK activation.Pharmacology research & perspectives · 2017Article
- Mitochondrial ROS, uncoupled from ATP synthesis, determine endothelial activation for both physiological recruitment of patrolling cells and pathological recruitment of inflammatory cells.Canadian journal of physiology and pharmacology · 2017Review
- Lysophosphatidic Acid Pretreatment Attenuates Myocardial Ischemia/Reperfusion Injury in the Immature Hearts of Rats.Frontiers in physiology · 2017Article
- Development of an Atlantic salmon heart endothelial cell line (ASHe) that responds to lysophosphatidic acid (LPA).In vitro cellular & developmental biology. Animal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThe bioactive lysophospholipids, lysophosphatidic acid (LPA) and sphingosine 1 phosphate (S1P), have potent effects on blood and vascular cells. This review focuses their potential contributions to the development of atherosclerosis, acute complications such as acute myocardial infarction, and chronic ischemic cardiac damage. RECENT
findingsExciting recent developments have provided insight into the molecular underpinnings of LPA and S1P receptor signaling. New lines of evidence suggest roles for these pathways in the development of atherosclerosis. In experimental animal models, the production, signaling, and metabolism of LPA may be influenced by environmental factors in the diet that synergize to promote the progression of atherosclerotic vascular disease. This is supported by observations of human polymorphisms in the lysophospholipid-metabolizing enzyme PPAP2B, which are associated with risk of coronary artery disease and myocardial infarction. S1P signaling protects from myocardial damage that follows acute and chronic ischemia, both by direct effects on cardiomyocytes and through stem cell recruitment to ischemic tissue. SUMMARY: This review will suggest novel strategies to prevent the complications of coronary artery disease by targeting LPA production and signaling. Additionally, ways in which S1P signaling pathways may be harnessed to attenuate ischemia-induced cardiac dysfunction will be explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.